First Author: P.Kalouda GREECE
Co Author(s): E. Kanonidou I. Zampros C. Skatharoudi E. Zopounidou D. Balatsoukas 0 0 0 0 0 0 0 0 0
Back to previous
Our purpose was to assess the efficacy and safety of intravitreal injections of ranibizumab as first line therapy for the management of neovascular age-related macular degeneration (wet AMD) in our practice.
Department of Ophthalmology, ‘’Hippokrateion’’ General Hospital of Thessaloniki, Thessaloniki, Greece.
The medical records of 53 patients (53 eyes), (25 male/28 female) with a mean age of 76.5 years old were examined retrospectively. All suffered from neovascular age-related macular degeneration confirmed by fluorescein angiography and optical coherence tomography. All eyes received initial three loading doses of anti-VEGF factor (ranibizumab 0.5 mg) at monthly intervals followed by as-needed regimen (pro re nata) with monthly follow up. Best-corrected visual acuity examination and central retinal thickness measurements were evaluated during the follow up period.
The mean follow up period was 12.8 months. The mean number of injections per patient was 5.8. The mean best corrected visual acuity was 0.725 logMAR at baseline and improved to 0.450 logMAR at final examination (p<0.05). Specifically, changes in visual acuity were found as follows: unchanged 37% (20 eyes), improved 46% (24 eyes) and deteriorated 17% (9 eyes). Τhere was also a significant OCT-determined mean central retinal thickness change (p<0.05). No injection complications or drug related side effects were recorded.
In our series of patients suffering from neovascular age-related macular degeneration, intravitreal injections of ranibizumab showed an improvement in visual acuity values with no ocular and systemic associated side-effects. These findings confirm the efficacy and safety of ranibizumab as standard first line therapy for neovascular age related macular degeneration in our practice.